Skip to main content
SpringerLink
Log in

Control of Copper in Wilson’s Disease and Diseases of Neovascularization, such as Cancer

  • Chapter
Handbook of Copper Pharmacology and Toxicology

  • 307 Accesses

Abstract

Over the last 20 yr our group has worked on the development of new anticopper drugs for the treatment of Wilson’s disease. This has led to the development of zinc and tetrathiomolybdate for specific indications in Wilson’s disease, which we will discuss in detail shortly.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brewer, G. J. and Yuzbasiyan-Gurkan, V. (1992) Wilson disease. Medicine 71, 139–164.

    Article  PubMed  CAS  Google Scholar 

  2. Scheinberg, I.H. and Sternlieb, I. (1984) Wilson’s disease, in Major Problems in Internal Medicine, Vol. 23. (Smith, L. H., Jr., ed.), W.B. Saunders, Philadelphia.

    Google Scholar 

  3. Schilsky, M. L. (1993) Wilson disease: genetic basis of copper toxicity and natural history. Semin. Liver Dis. 16, 83–95.

    Article  Google Scholar 

  4. Brewer, G. J. (2000) Recognition, diagnosis and management of Wilson’s disease. Proc. Soc. Exp. Biol. Med. 223, 39–49.

    Article  PubMed  CAS  Google Scholar 

  5. Brewer, G. J., Fink, J. K., and Hedera, P. (1999) Diagnosis and treatment of Wilson’s disease. Semin. Neurol. 19, 261–270.

    Article  PubMed  CAS  Google Scholar 

  6. Brewer, G. J. (2000) Wilson’s disease. (2000) Curr. Treat. Options Neurol. 2, 193–203.

    Article  PubMed  Google Scholar 

  7. Frommer, D. J. (1974) Defective biliary excretion of copper in Wilson’s disease. Gut 15, 125–129.

    Article  PubMed  CAS  Google Scholar 

  8. Gibbs, K. and Walshe, J. M. (1980) Biliary excretion of copper in Wilson’s disease. Lancet 2, 538–539.

    Article  PubMed  CAS  Google Scholar 

  9. O’Reilly, S., Weber, P. M., Oswald, M., and Shipley, L. (1971) Abnormalities of the physiology of copper in Wilson’s disease. III. The excretion of copper. Arch. Neurol, 25, 28–32.

    Article  PubMed  Google Scholar 

  10. Hill, G. M., Brewer, G. J., Prasad, A. S., Hydrick, C. R., and Hartmann, D. E. (1987) Treatment of Wilson’s disease with zinc: I. Oral zinc therapy regimens. Hepatology 7, 522–528.

    Article  PubMed  CAS  Google Scholar 

  11. Holden, J. M, Wolf, W. R., and Mertz, W. (1979) Zinc and copper in self selected diets. J. Am. Diet. Assoc. 75, 23–28,.

    PubMed  CAS  Google Scholar 

  12. Klevay, L. M, Reck, S. J., and Barcome, D. P. (1979) Evidence of dietary copper and zinc deficiencies. JAMA 241, 1916–1918.

    Article  PubMed  CAS  Google Scholar 

  13. Reiser, S., Smith, J. C., Jr., Mertz, W., Holbrok, J. T., Scholfield, D. J., Powell, A. S., et al. (1985) Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am. J. Clin. Nutr. 42, 242–251.

    PubMed  CAS  Google Scholar 

  14. Iyengar, V., Brewer, G. J., Dick, R. D., and Owyang, C. (1988) Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson’s disease. J. Lab. Clin. Med. 111, 267–274.

    PubMed  CAS  Google Scholar 

  15. Tanzi, R. E., Petrukhin, K., Chernov, I., Pellequer, J. L., Wasco, W., Ross, B., Romano, et al. (1993) The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genet. 5, 44–50.

    Article  Google Scholar 

  16. Yamaguchi, Y., Heiny, M. E., and Gitlin, J. D. (1993) Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun. 197, 271–277.

    Article  PubMed  CAS  Google Scholar 

  17. Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., and Cox, D. W. (1993) The Wilson’s disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nature Genet. 5, 327–337.

    Article  PubMed  CAS  Google Scholar 

  18. Terada, K., Schilsky, M. L., and Sugiyama, T. (1998) ATP7B (WND) protein. Int. J. Biochem. Cell Biol. 30, 1063–1067.

    Article  PubMed  CAS  Google Scholar 

  19. Kennedy, S. and Cox, D. W. (1999) Wilson disease mutation database. Provided by University of Alberta (http://www.medgen.med.ualberta.ca/database.html), accessed May 22, 2000.

  20. Akil, M., Schwartz, J. A., Dutchak, D., Yuzbasiyan-Gurkan, V., and Brewer, G. J. (1991) The psychiatric presentations of Wilson’s disease. J. Neurol. Psychol. Clin. Neurosci. 3, 377.

    CAS  Google Scholar 

  21. Sternlieb, I., Morell, A. G., Bauer, C. D., Combes, B., DeBobes-Sternberg, S., and Scheinberg, I. H. (1961) Detection of heterozygous carrier of the Wilson’s disease gene. J. Clin. Invest. 40, 707–715.

    Article  CAS  Google Scholar 

  22. Brewer, G. J., Dick, R. D., Yuzbasiyan-Gurkan, V., Johnson, V., and Wang, Y. (1994) Treatment of Wilson’s disease with zinc. XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. J. Lab. Clin. Med. 123, 849–858.

    PubMed  CAS  Google Scholar 

  23. Yuzbasiyan-Gurkan, V., Johnson, V., and Brewer, G. J. (1991) Diagnosis and characterization of presymptomatic patients with Wilson’s disease and the use of molecular genetics to aid in the diagnosis. J. Lab. Clin. Med. 118, 458–465.

    CAS  Google Scholar 

  24. Yuzbasiyan-Gurkan, V., Grider, A., Nostrant, T., Cousins, R. J., and Brewer, G. J. (1992) The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J. Lab. Clin. Med. 120, 380–386.

    PubMed  CAS  Google Scholar 

  25. Brewer, G. J., Hill, G. M., Prasad, A. S., Cossack, Z. T., and Rabbani, P. (1983) Oral zinc therapy for Wilson’s disease. Ann. Intern. Med. 99, 314–320.

    PubMed  CAS  Google Scholar 

  26. Hill, G. M., Brewer, G. J., Prasad, A. S., Hydrick, C. R., and Hartmann, D. E. (1987) Treatment of Wilson’s disease with zinc: I. Oral zinc therapy regimens. Hepatology 7, 522–528.

    Article  PubMed  CAS  Google Scholar 

  27. Hill, G. M., Brewer, G. J., Juni, J. E., Prasad, A. S., and Dick, R. D. (1986) Treatment of Wilson’s disease with zinc: II. Validation of oral 64copper uptake with copper balance. Am. J. Med. Sci. 12, 344–349.

    Article  Google Scholar 

  28. Brewer, G. J., Yuzbasiyan-Gurkan, V., and Dick, R. (1990) Zinc therapy of Wilson’s disease: VIII. Dose response studies. Trace Elements Exp. Med. 3, 227–234.

    Google Scholar 

  29. Brewer, G. J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R. D., and Wang, Y. (1993) Treatment of Wilson’s disease with zinc: XII. Dose regimen requirements. Am. J. Med. Sci. 305, 199–202.

    Article  PubMed  CAS  Google Scholar 

  30. Brewer, G. J., Dick, R. D., Johnson, V. D., Brunberg, J. A., Kluin, K. J., and Fink, J. K. (1998) The treatment of Wilson’s disease with zinc XV. Long-term follow-up studies. J. Lab. Clin. Med. 132, 264–278.

    Article  PubMed  CAS  Google Scholar 

  31. Walshe, J. M. (1982) Treatment of Wilson’s disease with trientine (triethylene tetramine) dichloride. Lancet 1, 643–647.

    Article  PubMed  CAS  Google Scholar 

  32. Brewer, G. J., Dick, R. D., Yuzbasiyan-Gurkan, V., Tankanow, R., Young, A. B., and Kluin, K. J. (1991) Initial therapy of Wilson’s disease patients with tetrathiomolybdate. Arch. Neurol. 48, 42–47.

    Article  PubMed  CAS  Google Scholar 

  33. Brewer, G. J., Dick, R. D., Johnson, V., Wang Y., Yuzbasiyan-Gurkan, V., Kluin, K., et al. (1994) Treatment of Wilson’s disease with tetrathiomolybdate I. Initial therapy in 17 neurologically affected patients. Arch. Neurol. 51, 545–554.

    Article  PubMed  CAS  Google Scholar 

  34. Brewer, G. J., Johnson, V., Dick, R. D., Kluin, K. J., Fink, J. K., and Brunberg, J. A. (1996) Treatment of Wilson’s disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch. Neurol. 53, 1017–1025.

    Article  PubMed  CAS  Google Scholar 

  35. Walshe, J. M. (1956) Penicillamine. A new oral therapy for Wilson’s disease. Am. J. Med. 156, 487–495.

    Article  Google Scholar 

  36. Brewer, G. J., Terry, C. A., Aisen, A. M., and Hill, G. M. (1987) Worsening of neurological syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch. Neurol. 44, 490–494.

    Article  PubMed  CAS  Google Scholar 

  37. Yuzbasiyan-Gurkan, V., Brewer, G. J., Abrams, G. D., Main, B., and Giacherio, D. (1989) Treatment of Wilson’s disease with zinc: V: Changes in serum levels of lipase, amylase and alkaline phosphatase in Wilson’s disease patients. J. Lab. Clin. Med. 114, 520–526.

    PubMed  CAS  Google Scholar 

  38. Brewer, G. J., Yuzbasiyan-Gurkan, V., Lee, D. Y., and Appelman, H. (1989) The treatment of Wilson’s disease with zinc VI. Initial treatment studies. J. Lab. Clin. Med. 114, 633–638.

    PubMed  CAS  Google Scholar 

  39. Brewer, G. J., Yuzbasiyan-Gurkan, V., and Johnson, V. (1991) The treatment of Wilson’s disease with zinc: IX. Response of serum lipids. J. Lab. Clin. Med. 118, 466–470.

    PubMed  CAS  Google Scholar 

  40. Brewer, G. J., Yuzbasiyan-Gurkan, V., Johnson, V., Dick, R.D., and Wang Y. (1993) Treatment of Wilson’s disease with zinc: XI. Interaction with other anticopper agents. J. Am. Coll. Nutr. 12, 26–30.

    PubMed  CAS  Google Scholar 

  41. Brewer, G. J., Johnson, V., and Kaplan, J. (1997) Treatment of Wilson’s disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J. Lab. Clin. Med. 129, 649–652.

    Article  PubMed  CAS  Google Scholar 

  42. Hoogenraad, T. U., Koevoet, R., and De Ruyter Korver, E. G. W. M. (1979) Oral zinc sulfate as long-term treatment in Wilson’s disease (hepatolenticular degeneration). Eur. Neurol. 18, 205–211.

    Article  PubMed  CAS  Google Scholar 

  43. Hoogenraad, T. U., Van den Hamer, C. J. A., Koevoet, R., and De Ruyter Korver, E. G. W. M. (1978) Oral zinc in Wilson’s disease. Lancet 2, 1262–1263.

    Article  PubMed  CAS  Google Scholar 

  44. Hoogenraad, T. U., Van Hattum, J., and Van den Hamer, C. J. A. (1987) Management of Wilson’s disease with zinc sulfate. Experience in a series of 27 patients. J. Neurol. Sci. 77, 137–146.

    Article  PubMed  CAS  Google Scholar 

  45. Nazer, H., Ede, R. J., Mowat, A. P., and Williams, R. (1986) Wilson’s disease: clinical presentation and use of prognostic index. Gut 27, 1377–1381.

    Article  PubMed  CAS  Google Scholar 

  46. Hoogenraad, T. U. (1996) Wilson’s disease, in Major Problems in Neurology, Vol. 30 (Warlow, C. P. and van Gijn, J., eds.). W.B. Saunders, London.

    Google Scholar 

  47. Keen, C. L., Mark-Savage, B., Lönnerdal, B., and Hurley, L. S. (1983) Teratogenic effects of o-penicillamine in rats: relation to copper deficiency. Drug Nutr. Interact. 2, 17–34.

    PubMed  CAS  Google Scholar 

  48. Mjolnerod, O. K., Dommerud, S. A., Rasmussen, K., and Gjeruldsen, S. T. (1971) Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1, 673–675.

    Article  PubMed  CAS  Google Scholar 

  49. Solomon, L., Abrams, G., Dinner, M., and Berman, L. (1977) Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. N. Engl. J. Med. 296, 54–55.

    Article  PubMed  CAS  Google Scholar 

  50. Rosa, F. W. (1986) Teratogen update: penicillamine. Teratology 33, 127–131.

    Article  PubMed  CAS  Google Scholar 

  51. Brewer, G. J., Johnson, V. D., Dick, R. D., Fink, J. K., Kluin, K. J., and Hedera, P. (2000). Treatment of Wilson’s disease with zinc. XVII. treatment during pregnancy. Hepatology 31, 364–370.

    Article  PubMed  CAS  Google Scholar 

  52. Food and Drug Administration. Teratologic Evaluation of FDA 71–49 (Zinc Sulfate). Food and Drug Research Laboratories, Inc. Prepared for Food and Drug Administration, United States Department of Commerce, Washington, DC, Publications PD-221 805, February 1973, and PB 267, June 1974.

    Google Scholar 

  53. Walshe, J. M. (1986) The management of pregnancy in Wilson’s disease treated with trientine. Q. J. Med. 58, 81–87.

    PubMed  CAS  Google Scholar 

  54. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175, 409–416.

    Article  PubMed  CAS  Google Scholar 

  55. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1, 27–31.

    Article  PubMed  CAS  Google Scholar 

  56. Folkman, J. (1997) Antiangiogenic therapy, in Cancer: Principles and Practice of Oncology ( De Vito, V., Rosenberg, and Hellman, eds.), Lippencott-Raven, Philadelphia, pp. 3075–3085.

    Google Scholar 

  57. Beckner, M. E. (1999) Factors promoting tumor angiogenesis. Cancer Invest. 17, 594–623.

    Article  PubMed  CAS  Google Scholar 

  58. Brem, S. (1999) Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 6, 436–458.

    PubMed  Google Scholar 

  59. Parke, A., Battacherjee, P., Palmer, R. M., and Lazarus, N. R. (1988) Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am. J. Clin. Pathol. 137, 1121–1142.

    Google Scholar 

  60. Raju, K. S., Alesandrii, G., Zinche, M., and Gullino, P. M. (1982) Ceruloplasmin, copper ions, and angiogenesis. J. Natl. Cancer Inst. 69, 1183–1188.

    PubMed  CAS  Google Scholar 

  61. Zinche, M., Jones, J., and Gullino, P. M. (1982) Role of prostoglandin E and copper in angiogenesis. J. Natl. Cancer Inst. 69, 475–482.

    Google Scholar 

  62. Brem, S. S., Zagzag, D., Tsanaclis, A. M. C., Gatley, S., Elkouby, M. P., and Brein, S. E. (1990) Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 137, 1121–1147.

    PubMed  CAS  Google Scholar 

  63. Brem, S., Tsanaclis, A. M., and Zagzag, D. (1990) Anticopper treatment inhibits pseudopdial protrusion and invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery 26, 391–396.

    Article  PubMed  CAS  Google Scholar 

  64. Merajver, S. D., Irani, J., van Golen, K., and Brewer, G. (1998) Copper depletion as an anti-angiogenic strategy in HER2-neu transgenic mice. Proceedings of the AACR Special Conference on Angiogenesis and Cancer, p. B11.

    Google Scholar 

  65. Linder, M. C., Houle, P. A., Isaacs, E., Moor, J. R., and Scott, L. E. (1979) Copper regulation of ceruloplasmin in copper-deficient rats. Enzyme 24, 23–35.

    PubMed  CAS  Google Scholar 

  66. Brewer, G. J., Dick, R. D., Grover, D. K., LeClaire, V., Tseng, M., Wicha, M., et al. (2000) Treatment of metastatic cancer with tetrathiomolybdate, and anticopper, antiangiogenic agent: I. Phase I study. Clin. Cancer Res. 6, 1–10.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. George J. Brewer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The National Health and Environmental Effects Research Laboratory, Research Triangle Park, NC, USA

    Edward J. Massaro

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brewer, G.J. (2002). Control of Copper in Wilson’s Disease and Diseases of Neovascularization, such as Cancer. In: Massaro, E.J. (eds) Handbook of Copper Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-288-3_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-288-3_27

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-266-7

  • Online ISBN: 978-1-59259-288-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation